Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Ophthalmology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GJA3 (Connexin-46) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GJA3 Extracellular Loop (ECL) Fusion Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed. |
View GJA3 Products |
| Gene Delivery | GJA3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Essential for functional channel assays. |
View GJA3 Products |
| Benchmark Ab | Anti-GJA3 Recombinant Antibody Recombinant positive control for flow cytometry and Western Blot validation. |
View GJA3 Products |
| Validator | GJA3 siRNA Set For target knockdown and specificity verification in phenotypic assays. |
View GJA3 Products |
| Related Target A | GJA1 (Connexin-43) Essential counter-screening target to prevent cardiotoxicity and systemic off-target effects. |
View GJA1 Products |
| Related Target B | GJA8 (Connexin-50) Closely related lens connexin; critical for evaluating ocular safety and selectivity profiles. |
View GJA8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Tetraspan Membrane Topology | High-titer Lentiviral vectors for stable overexpressing cell lines, preserving native gap junction architecture. |
| High Homology Off-Target Risks (Cx43/Cx50) | Full panel of recombinant extracellular loops for GJA1 and GJA8 to perform rigorous counter-screening. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the portfolio. |
| False Positives in Phenotypic Screens | Validating siRNA knockdown pools to confirm target-specific functional block. |
Live GJA3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GJA3 (Connexin-46 / Cx46) is undergoing a major paradigm shift. Historically characterized as a structural lens protein implicated in congenital cataracts, GJA3 has emerged as a critical driver of the cancer stem cell (CSC) phenotype in hypoxic tumor microenvironments, particularly in glioblastoma, breast cancer, and select solid tumors. Because GJA3 forms functional gap junctions and hemichannels that mediate the transfer of survival signals and metabolites under hypoxia, therapeutic strategies are moving rapidly toward monoclonal antibodies (mAbs) and small-molecule modulators that can selectively block these channels without disrupting ubiquitous connexins like GJA1 (Cx43).
As the first wave of GJA3-targeted agents enter preclinical and early clinical validation, the main R&D bottleneck lies in achieving strict selectivity. Systemic inhibition of gap junctions can lead to severe adverse events, making high-resolution screening against homologous proteins a prerequisite for clinical transition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biotech Startups | Glioblastoma, Triple-Negative Breast Cancer (TNBC) | Binding assays on native conformation (Requires GJA3 Lentivirus for stable cell lines). |
| Peptide Mimetics | Biopharma Innovators | Solid Tumors, Ischemic Retinopathy | Extracellular loop binding validation (Requires GJA3 ECL recombinant proteins). |
| Small Molecule Blockers | Oncology Discovery Consortiums | Hypoxic Solid Tumors, Cancer Stem Cell ablation | Dye-coupling and calcium flux functional assays (Requires GJA3 Lentivirus-transduced host cells). |